Definitive radiotherapy and Single-Agent radiosensitizing Ifosfamide in Patients with localized, irresectable Soft Tissue Sarcoma: A retrospective analysis
نویسندگان
چکیده
BACKGROUND AND PURPOSE Standard therapy for soft-tissue sarcomas remains complete resection. For primary radiotherapy local control rates of 30-45% have been reported. We analyzed retrospectively 11 cases of radiochemotherapy with single-agent ifosfamide in patients with macroscopic soft-tissue sarcomas. PATIENTS AND METHODS The patients were treated in irresectable high risk situations. Radiation therapy was performed with median 60 Gy. During the first and fifth week the concomitant chemotherapy with ifosfamide was added. Two patients received trimodal therapy with additional regional hyperthermia. RESULTS The therapy was completed in 73% of the patients. Average local control time was 91 months, median disease-free-survival/overall-survival was 8/26 months. Five-year rates for local control/disease free survival/overall survival were 70%/34%/34%. The limited prognosis is mainly caused by systemic treatment failure. CONCLUSIONS The data strongly suggest a better outcome of radiochemotherapy with ifosfamide compared to radiotherapy alone and radiotherapy in combination with other radiosensitizers.
منابع مشابه
Synovial Sarcoma of the Head and Neck: A Case of Childhood Soft Tissue Sarcoma
Although rare, synovial sarcoma is the most common malignant non-rhabdomyosarcomatous soft tissue sarcoma in children and adolescents. Synovial sarcoma typically involves the soft tissues of the extremities, especially near large joints, but it can occur anywhere in the body in locations far from joint spaces. Although this tumor typically affects adults in their fourth decade of life, nearly h...
متن کاملبهبودی کامل سینوویال سارکوما به دنبال کمورادیوتراپی نئوادجوانت
Synovial sarcoma (SS) is a rare but distinctive soft tissue sarcoma (STS) that displays epithelial differentiation. It consists of 5% to 10% of STSs. Surgery is the mainstay of treatment to prevent local recurrence and maximam five-year survival rate is 40 %. Recently, SS was noted to have increased post chemotherapy survival time and the sensitivity of SS to ifosfamide-based chemotherapy h...
متن کاملRadiotherapy for Ewing sarcoma: A 5 year experience from Iran cancer institute
Background: Ewing Sarcoma Family of Tumors (ESFTs) is the second most common primary tumors of bone in childhood. The decision regarding the optimal modality for achieving local tumor control remains uncertain. The aim of this study was to report the clinical features and outcome as well as reviewing risk factors in patients. Materials and Methods: This retrospective study included 75 ESFTs pat...
متن کاملIfosfamide in soft tissue sarcoma.
Ifosfamide, a congener of Cyclophosphamide, was originally introduced into clinical practice in 1971, but has not been widely used because of severe dose limiting urotoxicity, particularly when used as a single agent in large doses. A resurgence of interest in Ifosfamide followed the demonstration that urotoxicity could be lessened or abrogated by fractionated administration or, more effectivel...
متن کاملSystemic therapy of soft tissue sarcoma: an improvement in outcome.
Systemic therapy for the majority of patients with soft tissue sarcoma who require treatment of advanced unresectable or metastatic disease remains very unsatisfactory. Ifosfamide and doxorubicin remain the only agents in routine use. Treatment is usually given with palliative intent, and single-agent doxorubicin is generally regarded as the drug of choice. Inevitably, there have been efforts t...
متن کامل